Intellectual property

Patents

Sator Therapeutics' oncolytic virotherapy platform and its dendritic-cell systemic-delivery approach are protected by granted U.S. patents, assigned to Sator Therapeutics LLC.

U.S. Patent 11,253,558 B2

Optimized oncolytic viruses and uses thereof

Granted: Feb 22, 2022 · Assignee: Sator Therapeutics LLC · Publication: US 2018/0085411 A1

View on Google Patents →

U.S. Patent 12,606,796 B2

Delivery of oncolytic viruses using dendritic cells

Granted: 2026 · Assignee: Sator Therapeutics LLC · Publication: US 2020/0352993 A1

View on Google Patents →

Additional applications covering the platform are pending. For licensing or partnership inquiries, get in touch.